Please assess the completion status of the following clinical trial:

Trial Title: Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 17.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~1. Healthy male and female subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations~2. Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI=Weight (kg)/\[height(m)\]2~3. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and men, ages 18 to 75, inclusive~Exclusion Criteria:~1. Concurrent or use within 2 weeks of study drug administration, of marketed or investigational, drugs as specified in protocol~2. Other protocol-defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Part A Panel 1: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo single dose by mouth as specified
- Part A Panel 2: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo single dose by mouth as specified
- Part A Panel 3: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo single dose by mouth as specified
- Part A Panel 4: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo single dose by mouth as specified
- Part A Panel 5: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo single dose by mouth as specified
- Part A Panel 6: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo single dose by mouth as specified
- Part A Panel 7: BMS-986141 (Type: EXPERIMENTAL): Single dose by mouth as specified
- Part A Panel 8: BMS-986141 (Type: EXPERIMENTAL): Single dose by mouth as specified
- Part B Panel 1: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo by mouth as specified
- Part B Panel 2: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo by mouth as specified
- Part B Panel 3: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo by mouth as specified
- Part C Panel 1: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo by mouth as specified
- Part C Panel 2: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo by mouth as specified
- Part C Panel 3: BMS-986141 or Placebo (Type: EXPERIMENTAL): BMS-986141 or Placebo by mouth as specified
- Part D Panel 1: BMS-986141 and Aspirin (Type: EXPERIMENTAL): BMS-986141 and Aspirin by mouth as specified
- Part D Panel 1: Placebo matching BMS-986141 and Aspirin (Type: PLACEBO_COMPARATOR): BMS-986141 placebo and Aspirin by mouth as specified
- Part E Panel 1: BMS-986141 and Itraconazole (Type: EXPERIMENTAL): BMS-986141 and Itraconazole by mouth as specified

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete